Genital wart

Curaleaf International to Present Positive Clinical and Pre-Clincial Research

Retrieved on: 
Thursday, October 20, 2022
Research, Finance, Cannabis, Clinical Trials, Professional Services, Alternative Medicine, Health, Science, Natural Resources, News, International, Dyspareunia, Imperial College London, University of Insubria, Migraine, Cannabis, Inflammation, Growth, Conference, Woman, Science, Curaleaf, Brain-derived neurotrophic factor, Genital wart, Patient, Grassroots, Lists of diseases, Research, VBD, BDNF, CNSX, International Medical School, University of Milan, University, Sex, Trial of the century, Company, Vulval vestibule, MPFC, ROS, CSE, Pain, Canadian Securities Exchange, Karger Publishers, OTCQX, ECS, Plasma, PMN, Brain, Reactive oxygen species, Title, Pharmaceutical industry, Drug, Audit, CBD, Cannabinoid, Select, Cannabidiol

MD., F. Vicariotto, Prof. MD and Barbara Pacchetti, Chief Scientific Officer at Curaleaf International.

Key Points: 
  • MD., F. Vicariotto, Prof. MD and Barbara Pacchetti, Chief Scientific Officer at Curaleaf International.
  • For further information on the preclinical research to be presented, please see the footnote at the end of this announcement.
  • Curaleaf International (formerly EMMAC Life Sciences Group) is Europes largest vertically integrated cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production.
  • Curaleaf International assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

Genital Warts (GWs) Epidemiology Forecast Research Report 2022-2032 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 2, 2022
General Health, Infectious Diseases, Other Health, Health, Managed Care, Table, Diagnosis, United Kingdom, Epidemiology, Genital wart, Disease, GWS, Renewable energy

This "Genital Warts (GWs) - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Genital Warts (GWs) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This "Genital Warts (GWs) - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Genital Warts (GWs) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Genital Warts (GWs) epidemiology report gives a thorough understanding of the Genital Warts (GWs) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.
  • The report covers the detailed information of the Genital Warts (GWs) epidemiology scenario in seven major countries (US, EU5, and Japan).
  • The Genital Warts (GWs) epidemiology covered in the report provides historical as well as forecasted Genital Warts (GWs) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Global Warts Therapeutics Market (2021 to 2028) - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 13, 2021
Health, Pharmaceutical, Cryotherapy, Genital wart, Central, Therapy, Wart, Cantharidin, Texas Homecare, CAGR, COVID-19, Zinc, Time, Growth, Industry, Population, Poverty, Interferon, Prevalence, Hospital, Retinoid, Awareness, Face, Infection, Food, Recurrence, Bleomycin, STI, Salicylic acid, Pharmaceutical industry, Marketing

The "Global Warts Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Common Warts, Genital Warts, Flat Warts, and Others), Treatment (Physical Destruction, Immunomodulation, and Chemical Destruction), and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Warts Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Common Warts, Genital Warts, Flat Warts, and Others), Treatment (Physical Destruction, Immunomodulation, and Chemical Destruction), and End User" report has been added to ResearchAndMarkets.com's offering.
  • Based on type, the warts therapeutics market is segmented into common warts, genital warts, flat warts, and others.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the warts therapeutics market.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Wednesday, May 12, 2021
Medical specialties, Virology, Clinical medicine, Wart, Infectious causes of cancer, Plantar wart, Cantharidin, Genital wart, Dermatology, Molluscum contagiosum

The webcast replay will be available shortly after conclusion of the event for 30 days.\nVerrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions.

Key Points: 
  • The webcast replay will be available shortly after conclusion of the event for 30 days.\nVerrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions.
  • Verrica\xe2\x80\x99s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology.
  • Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts.
  • The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions.

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results

Retrieved on: 
Thursday, March 4, 2021
Medical specialties, Infectious causes of cancer, EGW, Wart, Genital wart, Microbiology, Clinical medicine

Verrica announced positive topline results from its Phase 2 CARE-1 clinical study of VP-102 in external genital warts (EGW).

Key Points: 
  • Verrica announced positive topline results from its Phase 2 CARE-1 clinical study of VP-102 in external genital warts (EGW).
  • Verrica reported a net loss of $13.0million for the fourth quarter of 2020, compared to a $7.6 million net loss for the same period in 2019.
  • Research and development expenses were $2.3million in the fourth quarter of 2020, compared to $4.0 million for the same period in 2019.
  • General and administrative expenses were $9.8million in the fourth quarter of 2020, compared to $4.0 million for the same period in 2019.

Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference

Retrieved on: 
Tuesday, January 19, 2021
Medical specialties, Virology, Clinical medicine, Infectious causes of cancer, EGW, Molluscum contagiosum, Wart, Genital wart, Dermatology, Imiquimod, Koebner phenomenon

The data were presented in poster format online for the 2021 Winter Clinical Dermatology Conference.

Key Points: 
  • The data were presented in poster format online for the 2021 Winter Clinical Dermatology Conference.
  • VP-102, our lead candidate, continues to demonstrate positive results as we advance development of the program in molluscum, external genital warts and common warts, three of the largest unmet needs in medical dermatology.
  • Data were also presented from Verricas Phase 2 CARE-1 clinical study of VP-102 in external genital warts (EGW).
  • Verricas late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and external genital warts, three of the largest unmet needs in medical dermatology.

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Retrieved on: 
Wednesday, December 23, 2020
Medical specialties, Virology, Clinical medicine, Molluscum contagiosum, Poxviruses, Infectious causes of cancer, Cantharidin, Wart, Genital wart, Plantar wart, Imiquimod, Molluscum dermatitis

We look forward to working with the FDA through the review process, and if approved, bringing VP-102 to patients as the first FDA-approved treatment option for molluscum.

Key Points: 
  • We look forward to working with the FDA through the review process, and if approved, bringing VP-102 to patients as the first FDA-approved treatment option for molluscum.
  • Without treatment, molluscum can last for an average of 13 months, and in some cases, up to several years.
  • Verricas late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and external genital warts, three of the largest unmet needs in medical dermatology.
  • Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts.

Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1)

Retrieved on: 
Tuesday, November 10, 2020
Medical specialties, Infectious causes of cancer, EGW, Microbiology, Wart, Genital wart, VP-102, Clinical medicine

Safety results from Part A supported use of VP-102 for both 6-hour and 24-hour treatment exposures in Part B.

Key Points: 
  • Safety results from Part A supported use of VP-102 for both 6-hour and 24-hour treatment exposures in Part B.
  • Topline analyses included data from the assessment of EGW at study visits at days 21, 42, 63, and 84.
  • In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and a Phase 2 study of VP-102 for the treatment of external genital warts.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Genital Warts Pipeline Insight Report 2020: Insights into 30 Companies & Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, October 9, 2020
Health, Biotechnology, RTT, Infectious causes of cancer, Medical specialties, Microbiology, Genital wart, Infections with a predominantly sexual mode of transmission, Clinical medicine, Wart

This Genital Warts - Pipeline Insight, 2020, report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape.

Key Points: 
  • This Genital Warts - Pipeline Insight, 2020, report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape.
  • This segment of the Genital Warts report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery.
  • This segment of the report provides insights about the different Genital Warts drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • phase II include Verrica Pharmaceuticals and others
    Genital Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

U.S. Genital Warts Market Analysis, 2017-2030 - Epidemiology, Drugs, Therapies, Vaccines, Companies, Unmet Needs, Reimbursement

Retrieved on: 
Tuesday, June 16, 2020
RTT, Infectious causes of cancer, Infectious diseases, Microbiology, Genital wart, Infections with a predominantly sexual mode of transmission, Medical specialties, Wart

DUBLIN, June 16, 2020 /PRNewswire/ -- The "Genital Warts (GWs) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 16, 2020 /PRNewswire/ -- The "Genital Warts (GWs) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Genital Warts (GWs) from 2017 to 2030.
  • The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
  • The Genital Warts (GWs) epidemiology division provides the insights about historical and current patient pool and forecasted trend for the United States.